An mRNA COVID-19 vaccine does not increase the short-term risk of relapses in people with multiple sclerosis (MS), a new study indicates. Di Filippo et al. analysed data from 324 people with MS who received the Pfizer/BioNTech BNT162b2 vaccine and were followed up for ≥2 months after their first dose. The incidence of clinical relapses in the 2 months after vaccination did not differ significantly from that in the 2 months before vaccination. The results support the recommendation for people with MS to receive the COVID-19 vaccine.